Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades15
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- TRADING UPDATES: Kelso raises stake in NCC; Transense joins project
3 May 2024 - Faron Pharmaceuticals extends funding agreement with IPF
30 Apr 2024 - Faron Pharmaceuticals reappoints former finance chief on interim basis
15 Apr 2024 - Faron Pharmaceuticals CFO stands down
15 Apr 2024 - UPDATE: Faron Pharmaceuticals promotes COO to CEO as father retires
8 Apr 2024 - Faron Pharmaceuticals promotes COO to CEO as founder steps back
8 Apr 2024 - Faron Pharmaceuticals taps Juho Jalkanen for CEO
8 Apr 2024 - Faron Pharmaceuticals secures funding to deliver next "milestones"
4 Apr 2024
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
TRADING UPDATES: Kelso raises stake in NCC; Transense joins project
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Allia...
Faron Pharmaceuticals extends funding agreement with IPF
(Sharecast News) - Faron Pharmaceuticals announced on Tuesday that it has extended its agreement with lender IPF to ensure continued financial support...
Faron Pharmaceuticals reappoints former finance chief on interim basis
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it appointed a new interim chief financial officer to replace the outgoing James O'Brien.
Faron Pharmaceuticals CFO stands down
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would ...
UPDATE: Faron Pharmaceuticals promotes COO to CEO as father retires
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace his father, the c...
Faron Pharmaceuticals promotes COO to CEO as founder steps back
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace the company's fou...
Faron Pharmaceuticals taps Juho Jalkanen for CEO
(Sharecast News) - Biopharmaceutical company Faron Pharmaceuticals named Dr Juho Jalkanen as its next chief executive officer on Monday.
Faron Pharmaceuticals secures funding to deliver next "milestones"
(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has successfully raised funds to support the phase two study of its bexmarilimab cance...
Follow the stocks
